{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05819021",
            "orgStudyIdInfo": {
                "id": "CLN-0107"
            },
            "organization": {
                "fullName": "Magnus Medical",
                "class": "INDUSTRY"
            },
            "briefTitle": "Open Label Optimization Study",
            "officialTitle": "An Open Label Optimization Study to Assess the Effectiveness of the SAINT\u00ae Neuromodulation System (NMS) to Treat Major Depressive Disorder",
            "acronym": "OLO",
            "therapeuticArea": [
                "Other"
            ],
            "study": "open-label-optimization-study"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-04-06",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-10-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-04-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-04-04",
            "studyFirstSubmitQcDate": "2023-04-17",
            "studyFirstPostDateStruct": {
                "date": "2023-04-19",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-20",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Magnus Medical",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this observational study is to demonstrate effectiveness in the treatment of Major Depressive Disorder\n\nThe primary objective is to assess the effectiveness in the treatment of Major Depressive Disorder using the CGI-I at the end of the treatment\n\nParticipants will receive 10 treatments per day for 5 days (M-F) of SAINT\u00ae",
            "detailedDescription": "This is a prospective, multi-center, open-label study.\n\nUp to 1000 adult subjects, in a major depressive episode, who have failed to receive satisfactory improvement from a prior antidepressant medication in the current episode, are eligible to participate in this study if they are deemed to be appropriate candidates for TMS.\n\nOverall study duration is expected to be approximately 4 years. The study duration per subject is anticipated to be approximately 1 year.\n\nHypothesis: The SAINT\u00ae Neuromodulation System will demonstrate effectiveness in the treatment of MDD as measured by CGI-I at the end of the treatment (cessation of stimulation)."
        },
        "conditionsModule": {
            "conditions": [
                "Major Depressive Disorder"
            ],
            "keywords": [
                "Major Depressive Disorder",
                "Depression",
                "Treatment Resistant Depression"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "OTHER",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 1000,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "SAINT\u00ae Stimulation",
                    "description": "All participants will receive 10 treatments per day for 5 days (M-F) of SAINT\u00ae stimulation therapy.",
                    "interventionNames": [
                        "Device: SAINT\u00ae Neuromodulation System (NMS)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DEVICE",
                    "name": "SAINT\u00ae Neuromodulation System (NMS)",
                    "description": "The SAINT\u00ae NMS utilizes a type of accelerated iTBS delivered to a personalized treatment target derived from a functional MRI scan. SAINT\u00ae was designed to optimize the individual patient response to treatment. This novel approach to TMS is accomplished by focusing on three critical aspects of the treatment that drive effect. These aspects are personalized stimulation target, total course dose of stimulation, and neurophysiologically relevant stimulation pattern.",
                    "armGroupLabels": [
                        "SAINT\u00ae Stimulation"
                    ],
                    "otherNames": [
                        "TMS"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Mean Clinical Global Impression Improvement Scale (CGI-I) score at the end of treatment (Day 5 SAINT\u00ae therapy)",
                    "description": "Clinical Global Impression-Improvement (CGI-I) score is based on a scale from zero (0) - Not Assessed to seven (7) Very Much Worse with lower scores showing improvement and higher scores showing little or no improvement.",
                    "timeFrame": "End of Stimulation Day 5"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Montgomery-Asberg Depression Rating Scale (MADRS) score change from baseline to cessation of stimulation in comparison with bioimaging assessments MADRS score change from baseline to cessation of stimulation in comparison with bioimaging assessments",
                    "description": "The rating is based on a clinical interview. Questions are asked using scales from zero (0) to six (6) with lower scores showing a better outcome and higher scores showing a worse outcome",
                    "timeFrame": "Baseline to End Stimulation Day 5"
                },
                {
                    "measure": "Cambridge Brain Science Tools assessment score change in comparison with change in MADRS scores from baseline to cessation of stimulation",
                    "description": "Assess aspects of cognition including reasoning, memory, attention and verbal ability on an online platform. Scores are automatically calculated on a scale from zero (0) to one hundred (100) and zero (0) to negative one hundred (-100) with positive numbers being associated with \"Best\" and negative numbers being associated with \"Worst\"",
                    "timeFrame": "Baseline to End of Stimulation Day 5"
                },
                {
                    "measure": "To test the durability of the antidepressant effect by assessing the Clinical Global Impression Severity Scale (CGI-S) after cessation of stimulation",
                    "description": "The Clinical Global Impression-Severity (CGI-S) is a brief clinician assessment that rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Score is based on a scale from zero (0) - Not Assessed to seven (7) Very Much Worse with lower scores showing improvement and higher scores showing little or no improvement.",
                    "timeFrame": "3, 6, 9, 12 month follow up visit"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Safety - Adverse Event Reporting assessment for causality and severity",
                    "description": "Any untoward medical occurrence in a participant treated with an investigational device, without regard to the possibility of a causal relationship with this treatment. Adverse events will be recorded and followed through all follow-up visits",
                    "timeFrame": "Consent through 12 month follow up visit"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Adult males or females, 18 and older, who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.\n2. Confirmed primary clinical diagnosis of major depressive disorder (MDD) without psychotic features consistent with DSM-V criteria.\n3. No medical conditions that would preclude the safe use of TMS.\n4. Primary psychiatrist has determined TMS to be an appropriate clinical option.\n5. Able to provide consent and comply with all study requirements.\n6. Negative pregnancy test at the intended time of SAINT\u2122 5-day acute course treatment and agreement to use effective birth control during SAINT\u00ae acute therapy.\n\nExclusion Criteria:\n\n1. Have any contraindication to TMS (section 2 User Manual).\n2. Have any contraindication to receiving an MRI\n3. Participants with an abnormal brain MRI as determined by PI, study physician or designee.\n4. Deemed by the PI, study physician or designee to be a high risk of suicide or has made a suicide attempt within the last 6 months.\n5. Treatment dose with cortical depth adjustment is greater than 120% motor threshold and cannot be completed.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Participants who fulfill all the inclusion criteria and none of the exclusion criteria will be enrolled into the study. Each participant will read and sign the IRB approved informed consent form prior to any screening or study procedures being performed. This open-label study involves an evaluation of the safety and effectiveness of an acute course of the SAINT\u00ae NMS.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jessica Hawkins",
                    "role": "CONTACT",
                    "phone": "650-525-4485",
                    "email": "jessica@magnusmed.com/https://www.magnusmed.com/clinical-trials/"
                },
                {
                    "name": "Marcia Gutierrez, BS",
                    "role": "CONTACT",
                    "phone": "415-350-3118",
                    "email": "marcia@magnusmed.com"
                }
            ],
            "locations": [
                {
                    "facility": "BrainHealth Solutions",
                    "status": "RECRUITING",
                    "city": "Costa Mesa",
                    "state": "California",
                    "zip": "92626",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Debra Hoffmeyer",
                            "role": "CONTACT",
                            "email": "bota4TMS@gmail.com"
                        },
                        {
                            "name": "Robert Bota, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.64113,
                        "lon": -117.91867
                    }
                },
                {
                    "facility": "LA TMS",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90025",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Hallie Houck",
                            "role": "CONTACT",
                            "email": "hallie@latms.com"
                        },
                        {
                            "name": "Ian Cook, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Integral TMS",
                    "status": "RECRUITING",
                    "city": "Sunnyvale",
                    "state": "California",
                    "zip": "94085",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Vera Costa",
                            "role": "CONTACT",
                            "phone": "669-600-3045",
                            "email": "integraltmsclinic@gmail.com"
                        },
                        {
                            "name": "Brent Solvason, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.36883,
                        "lon": -122.03635
                    }
                },
                {
                    "facility": "Acacial Research Center",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Sunnyvale",
                    "state": "California",
                    "zip": "94087",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.36883,
                        "lon": -122.03635
                    }
                },
                {
                    "facility": "Boston Precision Neurotherapeutics",
                    "status": "RECRUITING",
                    "city": "Natick",
                    "state": "Massachusetts",
                    "zip": "01760",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ann Boschini",
                            "role": "CONTACT",
                            "email": "Intakes@bpnclinic.com"
                        },
                        {
                            "name": "Tracy Barbour, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.28343,
                        "lon": -71.3495
                    }
                },
                {
                    "facility": "Fermata",
                    "status": "RECRUITING",
                    "city": "Brooklyn",
                    "state": "New York",
                    "zip": "11249",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Chelsey Fasano",
                            "role": "CONTACT",
                            "email": "info@fermata.health"
                        },
                        {
                            "name": "Owen Muir, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.6501,
                        "lon": -73.94958
                    }
                },
                {
                    "facility": "Seattle Neuropsychiatric Treatment Center",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Libby Kell",
                            "role": "CONTACT",
                            "email": "libby.kell@seattlentc.com"
                        },
                        {
                            "name": "Rebecca Allen, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003866",
                    "term": "Depressive Disorder"
                },
                {
                    "id": "D000003863",
                    "term": "Depression"
                },
                {
                    "id": "D000003865",
                    "term": "Depressive Disorder, Major"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019964",
                    "term": "Mood Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                },
                {
                    "id": "D000001526",
                    "term": "Behavioral Symptoms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7058",
                    "name": "Depression",
                    "asFound": "Depressive Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7061",
                    "name": "Depressive Disorder",
                    "asFound": "Depressive Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7060",
                    "name": "Depressive Disorder, Major",
                    "asFound": "Major Depressive Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M29783",
                    "name": "Depressive Disorder, Treatment-Resistant",
                    "relevance": "LOW"
                },
                {
                    "id": "M12402",
                    "name": "Neuroleptic Malignant Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M21835",
                    "name": "Mood Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4818",
                    "name": "Behavioral Symptoms",
                    "relevance": "LOW"
                },
                {
                    "id": "T4101",
                    "name": "Neuroleptic Malignant Syndrome",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}